AUG 1 7 2006

AMENDMENT TRANSMITTAL LETTER

Docket No. 04305/100H154-US2

Application No. 10/705,401-Conf. #4414

Filing Date November 10, 2003 Examiner C. L. Fronda Art Unit 1652

Applicant(s): Henrik Clausen et al.

METHODS TO IDENTIFY AGENTS MODULATING FUNCTIONS OF POLYPEPTIDE Invention: GALNAC-TRANSFERASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH

AGENTS AND THE USE OF SUCH AGENTS FOR PREPARING MEDICAMENTS

TO THE COMMISSIONER FOR PATENTS

Transmitted herewith is an amendment in the above-identified application.

The fee has been calculated and is transmitted as shown below.

CLAIMS AS AMENDED					
	Claims Remaining After Amendment	Highest Number Previously Paid	Number Extra Claims Present	Rate	
Total Claims	40	- 40 =		х	
Independent Claims	13	- 13 =		х	
Multiple Depend	dent Claims (ch	eck if applicabl	e)		
Other fee (pleas	se specify): E	xtension for res	ponse within s	econd month	225.00
TOTAL ADDIT	IONAL FEE FO	OR THIS AME	NDMENT:		225.00
Please char X A check in the payment by X The Director as described	credit card. For is hereby author delow.	225.00 prm PTO-2038	04-0100 in to cover is attached.	the amount of \$ the filing fee is end Deposit Account N	closed.
S. Peter Ludwin Attorney/Agent DARBY & DAR P.O. Box 5257	Reg. No.: 25,3 BY P.C.	ng or application	n processing	,	37 CFR 1.16 and 1.17 August 17, 2006



Docket No.: 04305/100H154-US2

(PATENT)

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re Patent Application of:

Henrik Clausen et al.

Application No.: 10/705,401

Filed: November 10, 2003 Art Unit: 1652

For: METHODS TO IDENTIFY AGENTS

MODULATING FUNCTIONS OF

POLYPEPTIDE GALNAC-TRANSFERASES, PHARMACEUTICAL COMPOSITIONS COMPRISING SUCH AGENTS AND THE USE OF SUCH AGENTS FOR PREPARING

MEDICAMENTS

Examiner: C. L. Fronda

Confirmation No.: 4414

RESPONSE TO RESTRICTION REQUIREMENT

Commissioner for Patents P.O. Box 1450 Alexandria, VA 22313-1450

Dear Sir:

INTRODUCTORY COMMENTS

In response to the Official Action mailed by the U.S. Patent and Trademark Office on June 13, 2006, please consider the following remarks and amendments.

Amendments to the Claims are reflected in the listing of claims which begins on page 2 of this paper.

Remarks/Arguments begin on page 10 of this paper.